119646-68-3

Basic information

• Product Name: 3-BROMO-5-TERT-BUTYL-2-HYDROXY-BENZALDEHYDE
• Synonyms: 3-BROMO-5-TERT-BUTYL-2-HYDROXY-BENZALDEHYDE;3-Bromo-5-tert-butylsalicylaldehyde;2-Hydroxy-3-broMo-5-tert-butyl-benzaldehyde
• CAS NO: 119646-68-3
• Molecular Formula: C₁₁H₁₃BrO₂
• Molecular Weight: 257.12
• Mol File: 119646-68-3.mol

Chemical Properties

• Boiling Point: 261.3°C at 760 mmHg
• Flash Point: 111.9°C
• Appearance: /
• Density: 1.409g/cm³
• Vapor Pressure: 0.00715mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-BROMO-5-TERT-BUTYL-2-HYDROXY-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-TERT-BUTYL-2-HYDROXY-BENZALDEHYDE(119646-68-3)
• EPA Substance Registry System: 3-BROMO-5-TERT-BUTYL-2-HYDROXY-BENZALDEHYDE(119646-68-3)

Safety Data

• Hazardous Substances Data: 119646-68-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-BROMO-5-TERT-BUTYL-2-HYDROXY-BENZALDEHYDE is used as a key intermediate in organic synthesis for the creation of various complex organic compounds. Its unique structure allows for the formation of new chemical entities through reactions such as condensation, substitution, and addition, facilitating the development of novel molecules with potential applications in different fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-BROMO-5-TERT-BUTYL-2-HYDROXY-BENZALDEHYDE is utilized as a starting material or building block in the synthesis of potential drug candidates. Its structural features make it a valuable component in the design of new molecules with therapeutic potential, contributing to the advancement of drug discovery and development processes.
Used in Drug Development:
3-BROMO-5-TERT-BUTYL-2-HYDROXY-BENZALDEHYDE is employed in drug development as a precursor for the synthesis of bioactive compounds. Its unique properties enable the exploration of its interactions with biological targets, aiding in the identification of new therapeutic agents with improved efficacy and selectivity.
Overall, 3-BROMO-5-TERT-BUTYL-2-HYDROXY-BENZALDEHYDE is a versatile and significant compound in the realm of chemistry and drug discovery, with applications spanning across various industries and research areas.

InChI:InChI=1/C11H13BrO2/c1-11(2,3)8-4-7(6-13)10(14)9(12)5-8/h4-6,14H,1-3H3

Upstream product

• 2198-66-5 2-bromo-4-tert-butylphenol 
• 2725-53-3 2-hydroxy-5-t-butylbenzaldehyde 
• 50-00-0 formaldehyd 
• 98-54-4 para-tert-butylphenol 
• 100-97-0 hexamethylenetetramine 

Downstream Products

• 119778-26-6 3-bromo-5-tert-butyl-2-hydroxy-benzaldehyde-oxime 
• 160154-68-7 3-(2'-pyridyl)-5-tert-butyl-2-hydroxybenzaldehyde 
• 960252-91-9 3-(2-naphthyl)-5-t-butylsalicylaldehyde 
• 960252-90-8 cis-8-formyl-6a,11b-dihydro-10-(2,2-dimethylethyl)naphtho[2,1-b]benzo[d]furan 
• 1086898-78-3 C₂₃H₂₅BrO₄ 
• 1086898-80-7 C₂₇H₃₃BrO₄ 
• 1262020-37-0 (Z)-2-benzylidene-7-bromo-5-tert-butyl-2,3-dihydrobenzofuran-3-ol 
• 2599-63-5 2-bromo-4-tert-butyl-6-(hydroxymethyl)phenol 
• 1262020-29-0 C₁₉H₁₉BrO₂ 
• 1415419-17-8 (R)-2-bromo-(4-tert-butyl)-6-(1-hydroxy-2-nitroethyl)phenol 

Relevant articles and documents

Ligand tuning in the chromium-salen-mediated asymmetric epoxidation of alkenes

A series of Cr(salen) complexes have been synthesised from 5-substituted-3-bromosalicylaldehydes and trans-1,2-cyclohexanediamine. These have been used to probe the Cr(salen)-mediated asymmetric epoxidation of alkenes. No simple correlation was found between the electronic character of the salen-substituents and the enantioselectivity - multiple oxidation pathways are proposed as a possible explanation. Enantioselectivities of up to 90% have been achieved using a novel, synthetically accessible Cr(salen) complex.

Synthesis of a tridentate ligand for use in TiIV-catalyzed acetate aldol addition reactions

A facile, practical synthesis and resolution of (±) -2′-amino-[1,1′-binaphthalen]-2-ol (1) is described, as well as the preparation of the tridentate Schiff base ligand 2 derived from condensation of 1 with 3-bromo-5-(tert-butyl)salicylaldehyde, which has been used in catalytic enantioselective acetate aldol addition reactions.

Synthesis and characterization of new extractants for Cu(II)

New extractants for Cu2+ ions in raw ore powders or waste water (fluid) were successfully synthesized recently in good yields. Their structures and purity were confirmed by 1H NMR and IR.

ALPHAvBETA1 INTEGRIN ANTAGONISTS

The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins ανβ1 and/or α5β1. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins ανβ3, ανβ5, ανβ6, ανβ8, and/or αIIbβ3.

Salicylaldehyde Hydrazones: Buttressing of Outer-Sphere Hydrogen-Bonding and Copper Extraction Properties

Salicylaldehyde hydrazones are weaker copper extractants than their oxime derivatives, which are used in hydrometallurgical processes to recover ～20% of the world's copper. Their strength, based on the extraction equilibrium constant Ke, can be increased by nearly three orders of magnitude by incorporating electron-withdrawing or hydrogen-bond acceptor groups (X) ortho to the phenolic OH group of the salicylaldehyde unit. Density functional theory calculations suggest that the effects of the 3-X substituents arise from a combination of their influence on the acidity of the phenol in the pH-dependent equilibrium, Cu2++2Lorg→[Cu(L-H)2]org+2H+, and on their ability to 'buttress' interligand hydrogen bonding by interacting with the hydrazone N-H donor group. X-ray crystal structure determination and computed structures indicate that in both the solid state and the gas phase, coordinated hydrazone groups are less planar than coordinated oximes and this has an adverse effect on intramolecular hydrogen-bond formation to the neighbouring phenolate oxygen atoms.

HETEROARYL DERIVATIVES AND USES THEREOF

The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Aryl Derivatives And Uses Thereof

The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

Studies on enzyme-cleavable dialkoxymethyl-cycloSaligenyl-2′, 3′-dideoxy-2′,3′-didehydrothymidine monophosphates

Recently we reported on conceptually new enzymatically activated cycloSal-pronucleotides. Now, we developed this concept further with new compounds of this type. The basic idea is fast intracellular cleavage of a functionalized group at the cycloSal residue that results in a rapid delivery of the nucleotide and thus an intracellular enrichment of the nucleotide. The introduction of a higher alkylated acylal group, the di-iso-butyryloxymethyl group, to the aromatic ring led to the expected higher stability of these prodrugs against enzymatic cleavage but also entailed surprisingly a decrease in hydrolysis stabilities and solubility problems. For some compounds, a separation of the two diastereomeric forms (RP or SP) was achieved. By X-ray structure analysis, the absolute configuration at the P-atom was assigned. For all separated diastereomers the (SP) form showed better antiviral activity than the (RP) form.

Synthesis of 3-aryl-5-t-butylsalicylaldehydes and their chiral Schiff base compounds

Six meta-substituted salicylaldehyde compounds have been prepared in 68-90% yields by the Suzuki-Miyaura coupling reaction using 3-bromo-5-t- butylsalicylaldehyde (1a) and arylboronic acids (2a-f) as reactants. Among the obtained products, 3-(4-fluorophenyl)-5-t-butylsalicylaldehyde (3b), 3-(4-methylphenyl)-5-t-butylsalicylaldehyde (3d), 3-(1-naphthyl)-5-t- butylsalicylaldehyde (3e), and 3-(2-naphthyl)-5-t-butylsalicylaldehyde (3f) have not been reported so far. A series of new Schiff base ligands (L1-L10) were obtained in 51-89% yields from these salicylaldehyde derivatives. Copyright Taylor & Francis Group, LLC.